ATE472336T1 - Zusammensetzungen und verfahren zur aktivierung der eigenen und allergischen immunität - Google Patents

Zusammensetzungen und verfahren zur aktivierung der eigenen und allergischen immunität

Info

Publication number
ATE472336T1
ATE472336T1 AT04796097T AT04796097T ATE472336T1 AT E472336 T1 ATE472336 T1 AT E472336T1 AT 04796097 T AT04796097 T AT 04796097T AT 04796097 T AT04796097 T AT 04796097T AT E472336 T1 ATE472336 T1 AT E472336T1
Authority
AT
Austria
Prior art keywords
compositions
methods
responses
elicit
treat
Prior art date
Application number
AT04796097T
Other languages
English (en)
Inventor
George Lowell
David Burt
David Jones
Joseph Zimmermann
Clement Rioux
Original Assignee
Id Biomedical Corp Quebec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Id Biomedical Corp Quebec filed Critical Id Biomedical Corp Quebec
Application granted granted Critical
Publication of ATE472336T1 publication Critical patent/ATE472336T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT04796097T 2003-10-22 2004-10-22 Zusammensetzungen und verfahren zur aktivierung der eigenen und allergischen immunität ATE472336T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51361403P 2003-10-22 2003-10-22
US55984204P 2004-04-06 2004-04-06
PCT/US2004/035041 WO2005042017A1 (en) 2003-10-22 2004-10-22 Compositions and methods for activating innate and allergic immunity

Publications (1)

Publication Number Publication Date
ATE472336T1 true ATE472336T1 (de) 2010-07-15

Family

ID=34555907

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04796097T ATE472336T1 (de) 2003-10-22 2004-10-22 Zusammensetzungen und verfahren zur aktivierung der eigenen und allergischen immunität

Country Status (8)

Country Link
US (4) US8173140B2 (de)
EP (2) EP2174665B1 (de)
JP (2) JP4966661B2 (de)
AT (1) ATE472336T1 (de)
CA (1) CA2543080C (de)
DE (1) DE602004027940D1 (de)
ES (2) ES2615169T3 (de)
WO (1) WO2005042017A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1372706B1 (de) * 2001-03-09 2010-12-01 ID Biomedical Corporation of Quebec Proteosom-liposaccharid-vakzine-adjuvans
US7255867B2 (en) 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
JP4966661B2 (ja) * 2003-10-22 2012-07-04 アイディー バイオメディカル コーポレイション オブ ケベック 生得的免疫およびアレルギー性免疫を活性化させるための組成物および方法
NZ578727A (en) * 2004-06-25 2011-03-31 Brigham & Womens Hospital Proteosome compositions and methods for treating neurological disorders
KR101856462B1 (ko) 2009-03-25 2018-05-10 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 병원체에 대한 포유동물의 선천성 면역 저항성의 자극을 위한 조성물
US9757448B2 (en) 2010-02-26 2017-09-12 The Brigham And Women's Hospital, Inc. Methods of treating cerebral amyloid angiopathy
DK2707480T3 (da) 2011-05-13 2017-11-13 Folia Biotech Inc Viruslignende partikler og fremgangsmåde til fremstilling heraf
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
WO2020182322A1 (en) * 2019-03-14 2020-09-17 Om Pharma Sa Method of treating and/or preventing asthma, asthma exacerbations, allergic asthma and/or associated conditions with microbiota related to respiratory disorders
WO2021222354A2 (en) * 2020-04-28 2021-11-04 Nova Southeastern University Compositions including alamandine peptides and methods for treatment of pulmonary disease using alamandine peptides
AU2022208435A1 (en) 2021-01-18 2023-08-10 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707543A (en) 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US5726292A (en) 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
DK0815235T3 (da) 1995-03-13 2003-04-22 Secr Defence Vacciner mod pest
PT854729E (pt) 1995-09-18 2004-08-31 Us Army Med Res Mat Com Usamrm Metodos melhorados para a producao de vacinas de subunidade multivalentes de proteossomas complexados nao covalentemente
JP3980884B2 (ja) 2000-02-15 2007-09-26 アイディー バイオメディカル コーポレイション オブ ケベック プロテオソーム・インフルエンザ・ワクチン
AU8640501A (en) * 2000-07-31 2002-02-13 Univ Yale Innate immune system-directed vaccines
EP1372706B1 (de) * 2001-03-09 2010-12-01 ID Biomedical Corporation of Quebec Proteosom-liposaccharid-vakzine-adjuvans
WO2002085933A1 (en) * 2001-04-20 2002-10-31 The Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
US8703146B2 (en) * 2001-04-20 2014-04-22 Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
WO2002100340A2 (en) * 2001-06-08 2002-12-19 Avant Immunotherapeutics, Inc. Improved vaccination against anthrax
US20030026780A1 (en) * 2001-07-18 2003-02-06 Hood Leroy E. Innate immunity mediated methods of treating pathological conditions
AU2004235815A1 (en) 2003-05-05 2004-11-18 Id Biomedical Corporation Of Quebec Vaccinating against infectious diseases using proteosomes
US7368537B2 (en) * 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
JP2007505836A (ja) * 2003-09-15 2007-03-15 アイディー バイオメディカル コーポレイション オブ ケベック 麻疹サブユニットワクチン
JP4966661B2 (ja) * 2003-10-22 2012-07-04 アイディー バイオメディカル コーポレイション オブ ケベック 生得的免疫およびアレルギー性免疫を活性化させるための組成物および方法
NZ578727A (en) 2004-06-25 2011-03-31 Brigham & Womens Hospital Proteosome compositions and methods for treating neurological disorders
KR20070052273A (ko) * 2004-06-30 2007-05-21 아이디 바이오메디컬 코포레이션 오브 퀘벡 코로나바이러스 감염의 치료를 위한 백신 조성물
WO2009132244A1 (en) * 2008-04-25 2009-10-29 Id Biomedical Corporation Of Quebec Methods for preparing immunogenic compositions

Also Published As

Publication number Publication date
CA2543080C (en) 2019-01-08
US8173140B2 (en) 2012-05-08
JP4966661B2 (ja) 2012-07-04
CA2543080A1 (en) 2005-05-12
EP1689433A1 (de) 2006-08-16
ES2615169T3 (es) 2017-06-05
JP2007509166A (ja) 2007-04-12
US20120276140A1 (en) 2012-11-01
ES2346441T3 (es) 2010-10-15
EP2174665A2 (de) 2010-04-14
EP2174665B1 (de) 2016-11-16
DE602004027940D1 (de) 2010-08-12
WO2005042017A1 (en) 2005-05-12
US9433672B2 (en) 2016-09-06
EP1689433B1 (de) 2010-06-30
US8709447B2 (en) 2014-04-29
US20090324639A1 (en) 2009-12-31
JP2011157380A (ja) 2011-08-18
US20090318337A1 (en) 2009-12-24
US20140234374A1 (en) 2014-08-21
EP2174665A3 (de) 2010-06-23

Similar Documents

Publication Publication Date Title
DE60026584D1 (de) Microbielles wirkstoffabgabesystem
WO2000054803A3 (en) Immunostimulatory nucleic acids and antigens
WO2004030608A3 (en) Nanoemulsion vaccines
WO2006135434A3 (en) Semi-soft c-class immunostimulatory oligonucleotides
DE602004027940D1 (de) Zusammensetzungen und verfahren zur aktivierung der eigenen und allergischen immunität
ATE426412T1 (de) Adjuvante influenza-vakzine
BRPI0206565A8 (pt) Composições e seus usos, e processo de produção de um arranjo de antígeno ordenado e repetitivo, de ocorrência não-natural
DE60207194D1 (de) Verfahren zur identifizierung, isolierung und herstellung von antigenen eines spezifischen pathogens
WO2003092610A3 (en) Methods of using cytokine antagonists to treat hiv infection and aids
WO2007026190A3 (en) Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
TW200507874A (en) Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
WO2005111057A3 (en) Immunostimulatory nucleic acids for inducing il-10 responses
WO2004058157A3 (en) Yeast-based vaccines as immunotherapy
WO2001060402A3 (en) Proteosome influenza vaccine
WO2003059381A3 (en) Immunogenic preparations and vaccines on the basis of mrna
WO2008039267A3 (en) Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
ATE404196T1 (de) Rapamycin und il-10 zur behandlung von autoimmunerkrankungen
DE60144240D1 (de) Zusammensetzung mit immunogenen mikroteilchen
DE60236318D1 (de) Präparationen grampositiver bakterien zur behandlung von krankheiten mit immunfehlregulation
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
WO2004032860A3 (en) Hiv vaccine formulations
EP4295862A3 (de) Coronavirus-impfstoff
CA2519806A1 (en) Composition comprising iscom particles and live micro-organisms
WO2002034287A3 (en) Therapeutic vaccine formulations containing chitosan
EP1262491A3 (de) Nicht-anaphylaktogene IgE Impfstoffe

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties